Related Experiment Videos

[Protective effects of incretin on atherosclerosis]

Tomoya Mita1, Hirotaka Watada

  • 1Department of Medicine, Metabolism and Endocrinology, Juntendo University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 21, 2011
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) shows promise in protecting against atherosclerosis in type 2 diabetes patients. Further research is needed to confirm its cardiovascular benefits beyond glucose control.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Type 2 diabetes significantly increases the risk of atherosclerotic disease.
  • Therapeutic strategies aim to inhibit atherosclerosis progression in diabetic patients.

Purpose:

  • To explore the vascular protective effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes.
  • To investigate GLP-1's potential to mitigate atherosclerosis progression.

Summary:

  • Exogenous glucagon-like peptide-1 (GLP-1) and its receptor agonists demonstrate direct beneficial effects on vascular cells, including endothelial cells, monocytes/macrophages, and vascular smooth muscle cells.
  • These vascular effects occur independently of glucose-lowering actions.
  • GLP-1 shows potential for protecting against atherosclerosis progression.

Impact:

  • GLP-1 may offer a novel therapeutic avenue for reducing cardiovascular events in type 2 diabetes.
  • Further experimental studies are required to elucidate the precise mechanisms of GLP-1's vascular actions.
  • Large-scale clinical trials are necessary to validate GLP-1's efficacy in preventing cardiovascular outcomes.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...